Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). Xiong W, Li Y, Huang J, He G, et al. PLoS One 2026;21:e0345281.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xiong W, Li Y, Huang J, He G, et al. Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). PLoS One 2026;21:e0345281.
PMID: 41860942